AdvtBy ,ETHealthWorldJoin the community of 2M+ industry professionals Subscribe to our newsletter to get latest insights & analysis. Its strategic location in Africa and evolving pharmaceutical landscape provide Venus Remedies with an opportunity to contribute positively to the region's healthcare sector. The $46.8 billion pharmaceutical market of Africa, as of 2022, is expected to grow at a CAGR of 8.3 per cent to reach $110.9 billion by 2023. This certification is a step towards enhancing the company's presence in Africa.Saransh Chaudhary, CEO, Venus Medicine Research Centre, said, “The GMP certification from Libya adds to Venus Remedies' portfolio of international approvals from 25 regulators, complementing our existing certifications in Africa from Morocco, South Africa , Tanzania, Kenya, Uganda Sudan , and other African countries. This GMP certification reflects our collaborative efforts in the African pharmaceutical industry, a key focus area of our global expansion strategy.” Akshansh Chaudhary , Executive Director, Venus Remedies, said, “We are thankful to our customers, partners, and stakeholders for their constant support.
